Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.50 |
| ▸ | PI4KA | P42356 | 3/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | AHCY | P23526 | 5/20 | 0.42 |
| ▸ | ADCY5 | O95622 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599251 | 1.00 | ADORA2A (0.50) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL599250 | 0.80 | ADORA2A (0.51) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL598755 | 0.77 | ADORA2A (0.62) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL599247 | 0.74 | ADORA2A (0.56) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9470633 | 0.70 | ADORA2A (0.71) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL600631 | 0.69 | ADORA2A (0.49) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL28984637 | 0.69 | ADORA2A (1.00) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6045512 | 0.68 | ADCY5 (0.62) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6045801 | 0.68 | ADCY5 (0.62) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6045575 | 0.68 | ADCY5 (0.62) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114994-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-11 | — | — | US | disclosed |
| US-7495006-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2009-02-24 | — | — | US | disclosed |
| US-20060223835-A1 | 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | HAVCR2, PNP, PCNA | ADORA2A 623/4885PI4KA 1116/4885PI4K2B 1114/4885 |
| US-20060223835-A1 | 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | HAVCR2, PNP, DCTD | ADORA2A 570/4885PI4KA 1271/4885PI4K2B 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.